Time to rethink clinically important outcomes in platelet transfusion trials
Nancy M. Heddle,
Donald M. Arnold,
Kathryn E. Webert,
Nancy M. Heddle
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorDonald M. Arnold
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorKathryn E. Webert
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorNancy M. Heddle,
Donald M. Arnold,
Kathryn E. Webert,
Nancy M. Heddle
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorDonald M. Arnold
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorKathryn E. Webert
From the Department of Medicine and the Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
Search for more papers by this authorNancy M. Heddle, MSc, FCSMLS(D), McMaster University, HSC 3H50, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada; e-mail: [email protected].
REFERENCES
- 1
Miller AB,
Hoogstraten B,
Staquet M,
Winkler A.
Reporting results of cancer treatment.
Cancer
1981; 47: 207-14.
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 2 Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337: 1870-5.
- 3 McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-41.
- 4 Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA, SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-73.
- 5 Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
- 6 Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43: 742-52.
- 7 Cook RJ, Heddle NM, Rebulla P, Sigouin CS, Webert KE. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 2004; 44: 1135-42.
- 8 Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18: 153-67.
- 9 Slichter SJ. Platelet transfusion therapy. Hematol Oncol Clin North Am 2007; 21: 697-729, vii.
- 10 Arnold DM, Lim W. The use and abuse of surrogate endpoints in clinical research in transfusion medicine. Transfusion 2008; 48: 1547-9.
- 11 Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-44.
- 12 Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-8.
- 13 van RD, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de GG, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L, euroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33.
- 14 The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
- 15 Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
- 16 Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
- 17 Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91: 1530-7.
- 18 Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003; 289: 2554-9.
- 19 Montori VM, Permanyer-Miralda G, Ferreira-Gonzalez I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. BMJ 2005; 330: 594-6.
- 20 Ross S. Composite outcomes in randomized clinical trials: arguments for and against. Am J Obstet Gynecol 2007; 196: 119-6.
- 21 la Cour JL, Brok J, Gotzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ 2010; 341: c3653.
- 22 Cordoba G, Schwartz L, Woloshin S, Bae H, Gotzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ 2010; 341: c3920.
Citing Literature
